Each CD includes the full-color, searchable, PDF files of articles and formulations from the Journal.

CD Prices
1 = $95
2 to 5 = $85 each
6 to 9 = $75 each
10 + = $65 each

Library CD
Volume 12, 2008 CD
Six back issues from 2008 on one convenient CD.
Permanent storage and easy retrieval of IJPC articles and formulations.
Only $95 per CD
  • Print journal articles in color from the PDF file for your marketing needs.
  • Eliminate long searches through past issues for formulations, compatibility studies, standard operating procedures, marketing ideas, and literature reviews.

This CD contains the following articles listed by volume, issue and page number:

Issues Included
Volume/Issue Date Title
Vol. 12 No. 1 January/February 2008 Compounding for Hospice and Cancer Patients
Vol. 12 No. 2 March/April 2008 Compounding Around the World
Vol. 12 No. 3 May/June 2008 Pain Management
Vol. 12 No. 4 July/August 2008 Hormone Replacement Therapy
Vol. 12 No. 5 September/October 2008 Veterinary Compounding
Vol. 12 No. 6 November/December 2008 Arthritis and Immunological Diseases

Volume 12, 2008 CD ARTICLES

Volume12, 2008 CD ARTICLES
Title (Click for Details) Vol/Issue Page
PreScription: Year Number 12…And Still Much Work to Do Vol. 12 No. 1 4
Intravitreal Bevacizumab for Choroidal Neovascularization in Age-Related Macular Degeneration Vol. 12 No. 1 8
Cancer-Related Terminology: Glossaries for Compounding Pharmacists and Their Clients Vol. 12 No. 1 16
Hospice and Compounding Pharmacy: Once Inseperable Vol. 12 No. 1 28
Disposing of Expired Drugs and Chemicals: New Options for Compounders Vol. 12 No. 1 38
Websites: Keeping Current in 2008 Vol. 12 No. 1 48
Quality-Control Analytical Methods: Stability Versus Potency Testing: The Madness is in the Method Vol. 12 No. 1 50
Basics of Compounding: Considerations for Implementing United States Pharmacopeia Chapter <797> Pharmaceutical Compounding--Sterile Preparations, Part 5: Verification of Accuracy, Sterility, and Sterilization of Compounded Preparations Vol. 12 No. 1 54
Calculations: Compounding for Cancer Patients Vol. 12 No. 1 62
Standard Operating Procedure: Compliance with the Health Insurance Portability and Accountability Act (HIPAA) of 1996 Vol. 12 No. 1 63
Cyclosporine Topical Gel Vol. 12 No. 1 64
Diclofenac Sodium 1% Soft-Patch Gel Vol. 12 No. 1 65
Diclofenac Sodium 1% Soft-Patch Lipophilic Gel Vol. 12 No. 1 66
Diltiazem 5% in Lipoderm, Veterinary Vol. 12 No. 1 67
Emetine Hydrochloride 30-mg/mL Injection Vol. 12 No. 1 68
Flosulide 10-mg/mL Injection Vol. 12 No. 1 69
Pentoxifylline 20-mg/mL Oral Suspension Vol. 12 No. 1 70
Piroxicam 1% Soft-Patch Lipophilic Gel Vol. 12 No. 1 71
Piroxicam 1% Soft-Patch Topical Gel Vol. 12 No. 1 72
Trimethoprim 10-mg/mL Oral Suspension Vol. 12 No. 1 73
Specialty Compounding for Improved Patient Care: 2006 National Survey of Compounding Pharmacists Vol. 12 No. 1 74
Room Temperature Stability of Injectable Succinylcholine Dichloride Vol. 12 No. 1 83
2007 Reviewers Vol. 12 No. 1 86
PostScription: Consumer Options for Disposal of Unused Medications Vol. 12 No. 1 87
PreScription: Compounding Around the World Vol. 12 No. 2 92
Current Compounding Practices in Europe Vol. 12 No. 2 94
Compounding Around the World Vol. 12 No. 2 102
Establishing a Quality-Assurance Program for Hospital Compounding Vol. 12 No. 2 116
Hormone Therapy: It's Time for a Second Opinion Vol. 12 No. 2 122
Newsletters: An Essential Marketing Tool Vol. 12 No. 2 128
Quality-Control Analytical Methods: Minimizing the Probability of Out-of-Specification Preparations: Results that Make You Say…Hmmm! Vol. 12 No. 2 130
Basics of Compounding: Considerations for Implementing United States Pharmacopeia Chapter <797> Pharmaceutical Compounding--Sterile Preparations, Part 6: 2008 Revisions to Chapter <797> Vol. 12 No. 2 136
Calculations Vol. 12 No. 2 145
Acyclovir 5% Topical Ointment Vol. 12 No. 2 146
Alum 6.5% Topical Cream Vol. 12 No. 2 147
Aminacrine Hydrochloride 0.1% Cream Vol. 12 No. 2 148
Butesin Picrate 1% ointment Vol. 12 No. 2 149
Carbamazepine Topical Preparations Vol. 12 No. 2 150
Chlorhexidine Gel Vol. 12 No. 2 151
EDTA 1% Cream Vol. 12 No. 2 152
Erythromycin 1% and Neomycin Sulfate Ointment Vol. 12 No. 2 153
Heparin Gel-Cream Vol. 12 No. 2 154
Hydrogen Peroxide 8% Cream Vol. 12 No. 2 155
Compatibility and Stability of Palonosetron Hydrochloride with Four Neuromuscular Blocking Agents During Simulated Y-Site Administration Vol. 12 No. 2 156
Chemical Stability of Tramadol Hydrochloride Injection Vol. 12 No. 2 161
Pharmaceutical Development of Enteric-Release Hard Gelatin Capsules in the Compounding Setting Vol. 12 No. 2 163
Compatibility and Stability of Palonosetron Hydrochloride with Gentamicin, Metronidazole, or Vancomycin During Simulated Y-Site Administration Vol. 12 No. 2 170
PostScription: Accreditation by the Pharmacy Compounding Accreditation Board: Raising the Bar for Patient Care Vol. 12 No. 2 174
PreScription: Pain! Vol. 12 No. 3 180
Topical Treatment of Neuropathic Pain Vol. 12 No. 3 182
Compounded Local Anesthetics to Minimize Pain from Medical Procedures Vol. 12 No. 3 192
Dilution and Compounding of Ziconotide for Intrathecal Administration Vol. 12 No. 3 200
Pharmacy Compounding at the University of Connecticut: Secundum Artem et Scientia Vol. 12 No. 3 208
Developing and Implementing a Clinical Pharmacy Rotation in a Community Compounding Pharmacy Vol. 12 No. 3 213
Microbial Air-Sampling Equipment, Part 1: Meeting United States Pharmacopeia Chapter <797> Standards Vol. 12 No. 3 216
Communication with Pharmacy Technicians: How to Reduce Stress and Improve Pharmacy Operations Vol. 12 No. 3 230
Obtaining Accreditation by the Pharmacy Compounding Accreditation Board, Part 3: Developing a Program of Quality Assurance and Continuous Quality Improvement Vol. 12 No. 3 234
Litigating the Legality of Compounding: The Medical Center Pharmacy Case Vol. 12 No. 3 238
Developing a Niche Marketing Strategy Vol. 12 No. 3 242
Web 2.0 and Health 2.0: Are You In? Vol. 12 No. 3 244
A Process Verification Model for Quality Assurance in a Compounding Pharmacy Vol. 12 No. 3 247
Basics of Compounding: Considerations for Implementing United States Pharmacopeia Chapter <797> Pharmaceutical Compounding--Sterile Preparations, Part 7: Microbial Contamination Risk Levels, 12-Hour Use, and Immediate Use Vol. 12 No. 3 252
Calculations Vol. 12 No. 3 258
Standard Operating Procedure: Dealing with Patients Experiencing Pain: Presenting without a Prescription Vol. 12 No. 3 259
African Scalp Lotion Vol. 12 No. 3 260
Benzyl Benzoate Lotion Vol. 12 No. 3 261
Calcium Gluconate 2.5% Topical Gel Vol. 12 No. 3 262
Lubricating Gel Vol. 12 No. 3 263
Meloxicam 0.3% Topical Gel Vol. 12 No. 3 264
Miconazole Nitrate 2%, Deoxy-D-Glucose 0.2%, and Hydrocortisone 0.4% Lip Balm Vol. 12 No. 3 265
Potassium Nitrate/Benzocaine/Tetracaine Dental Gel Vol. 12 No. 3 266
Promethazine Hydrochloride 2.5-mg/mL Rectal Solution Vol. 12 No. 3 267
Tolnaftate 1% Antifungal Microemulsion Vol. 12 No. 3 268
Valsartan 4-mg/mL Oral Liquid Vol. 12 No. 3 269
Evaluation of the Percutaneous Absorption of Promethazine Hydrochloride, In Vitro, Using the Human Ex Vivo Skin Model Vol. 12 No. 3 270
Chemical Stability of Naltrexone Hydrochloride Injection Vol. 12 No. 3 274
Compatibility of Caspofungin Acetate Injection with Other Drugs During Simulated Y-Site Coadministration Vol. 12 No. 3 276
PostScription: A Contemporary Perspective on Compounding Education Vol. 12 No. 3 279
PreScription: First Estriol, Then What? Vol. 12 No. 4 284
Estriol: Women's Choice vs. A Manufacturer's Greed Vol. 12 No. 4 286
Transdermal Progesterone: Effects on Menopausal Symptoms and on Thrombotic, Anticoagulant, and Inflammatory Factors in Postmenopausal Women Vol. 12 No. 4 295
The Magic of Magnesium Vol. 12 No. 4 306
Progesterone and Traumatic Brain Injury: A Review of Literature Vol. 12 No. 4 310
Beyond-Use Dating, Labeling, Delivery, and Storage of Compounded and Repackaged Mediations in a Hospital or Institutional Setting Vol. 12 No. 4 316
Microbial Air-Sampling Equipment, Part 2: Experiences of Compounding Pharmacists Vol. 12 No. 4 321
Recommendations for Overcoming Barriers to Medication Therapy Management Implementation, Part 1: Review of Literature Vol. 12 No. 4 329
Using Readily Available Technology to Start or Enhance Pharmacy-Based Immunization Vol. 12 No. 4 334
Marketing for Your Community Vol. 12 No. 4 338
Quality-Control Analytical Methods: Homogeneity of Dosing Forms Vol. 12 No. 4 340
Basics of Compounding: Considerations for Implementing United States Pharmacopeia Chapter <797> Pharmaceutical Compounding--Sterile Preparations, Part 8; Stability and Beyond-Use Dating Vol. 12 No. 4 344
Calculations Vol. 12 No. 4 354
Chloroxylenol 1% and Chlorhexidine Diacetate 1% Topical Powder Vol. 12 No. 4 355
Silicone Cream Vol. 12 No. 4 356
Sodium Chloride 0.9% Ointment Vol. 12 No. 4 357
Squalene 0.2% Cream Vol. 12 No. 4 358
Sucralfate and Hyaluronic Acid Ointment Vol. 12 No. 4 359
Tretinoin and (-)Alpha-Bisabolol Gel Vol. 12 No. 4 360
Tretinoin and Dexpanthenol Gel Vol. 12 No. 4 361
Ultrasonic Adhesive Gel Vol. 12 No. 4 362
Vitamin A Suppository Vol. 12 No. 4 363
Zirconium Oxide Lotion Vol. 12 No. 4 364
Lack of Commercial Oral Drug Formulations for Children in Two Hospital Group Purchasing Agreements in France and Canada Vol. 12 No. 4 365
Physical and Chemical Stability of Palonosetron Hydrochloride with Glycopyrrolate and Neostigmine During Simulated Y-Site Administration Vol. 12 No. 4 368
Chemical Stability of Perphenazine in Two Commercially Available Vehicles for Oral Liquid Dosage Forms Vol. 12 No. 4 372
PostScription: It Is Not Just What You Say…But How You Say It! Vol. 12 No. 4 375
PreScription: Compounding Around the World Vol. 12 No. 5 382
Canine Public Servants: Caring for Drug Detection Dogs Vol. 12 No. 5 384
Transdermal Amlodipine Besylate in Lipoderm for the Treatment of Feline Hypertension: A Report of Two Cases Vol. 12 No. 5 392
Veterinary Compounding for Myasthenia Gravis Vol. 12 No. 5 398
Equine Anesthesia: Triple Drip Vol. 12 No. 5 402
Publication Expansion of United States Pharmacopeial Convention's Veterinary Standards and Clinical Information Vol. 12 No. 5 405
Golden Ticket to the United States Pharmacopeial Convention's Veterinary Internship Vol. 12 No. 5 410
Medication Therapy Management Implementation, Part 2: Study Methodologies, Barriers, and Recommendations to Overcome Barriers Vol. 12 No. 5 414
Insurance for the Compounding Pharmacy Business, Part 1: Who Is Covered? Vol. 12 No. 5 420
Excipient Choices for Special Populations Vol. 12 No. 5 426
Obtaining Accreditation by the Pharmacy Compounding Accreditation Board, Part 4L Tips for "Last Minute" Preparations Vol. 12 No. 5 432
Technology for the Patient-Centric Pharmacy Vol. 12 No. 5 434
Marketing: Taking Your Show on the Road Vol. 12 No. 5 438
Basics of Compounding: Considerations for Implementing United States Pharmacopeia Chapter <797> Pharmaceutical Compounding--Sterile Preparations, Part 9: Immediate-Use Compounded Sterile Preparations Vol. 12 No. 5 440
Calculations Vol. 12 No. 5 444
Aceclofenac 1.5% Gel-Cream Vol. 12 No. 5 446
Acetaminophen 10-mg/mL Rectal Solution Vol. 12 No. 5 447
Carnitine 400-mg/mL and Coenzyme Q10 10-mg/mL Solution Vol. 12 No. 5 448
Dichlorobenzyl Alcohol Tooth Gel Vol. 12 No. 5 449
Estradiol 0.1% Vaginal Solution Vol. 12 No. 5 450
Flurandrenolide Topical Film Vol. 12 No. 5 451
Ketoprofen 20% Topical Solution Vol. 12 No. 5 452
Lidocaine Adhesive System Gel Vol. 12 No. 5 453
Piroxicam 5% and Dexpanthenol 5% Gel Vol. 12 No. 5 454
Propafenone 1.5-mg/mL Oral Liquid Vol. 12 No. 5 455
Testing the Long-Term Stability of Vancomycin Ophthalmic Solution Vol. 12 No. 5 456
Compatibility and Stability of Palonosetron Hydrochloride with Lactated Ringer's, Hetastarch in Lactated Electrolyte, and Mannitol Injections During Simulated Y-Site Administration Vol. 12 No. 5 460
Chemical Stability of Admixtures Combining Ziconotide with Fentanyl or Sufentanil During Simulated Intrathecal Administration Vol. 12 No. 5 463
PostScription: The International Society of Pharmaceutical Compounding: A Discussion of Its Importance from the Perspective of ISPhC Leadership Vol. 12 No. 5 467
Prescription: Is "Globalization" a Good Idea? Vol. 12 No. 6 474
Arthritis Epidemiology Impacts Pharmacists Vol. 12 No. 6 476
Compounding Challenges for Immunocompromised Patients Vol. 12 No. 6 482
Differentiation and Treatment of Hypothyroidism, Functional Hypothyroidism, and Functional Metabolism Vol. 12 No. 6 488
Case Reports: Compounding to Relieve Arthritis Pain Vol. 12 No. 6 498
Symbols: Historic and Current Uses Vol. 12 No. 6 505
Medication Therapy Management Implementation, Part 3: Barriers and Recommendations to Overcome Barriers Vol. 12 No. 6 508
Insurance for the Compounding Pharmacy Business, Part 2: What, When, and Where Vol. 12 No. 6 514
Quality-Control Analytical Methods: Overview of Beyond-Use Dating for Compounded Sterile Preparations Vol. 12 No. 6 524
Basics of Compounding: United States Pharmacopeia General Chapter <797> Pharmaceutical Compounding--Sterile Preparations, Part 10: First Revision: The Main Changes, Events, and Rationale Vol. 12 No. 6 530
Branding: Give Your Small Business a Big Image Vol. 12 No. 6 537
Calculations Vol. 12 No. 6 539
Cyclobenzaprine Hydrochloride 0.5% and Diclofenac Sodium 3% in Pluronic Lecithin Organogel Vol. 12 No. 6 540
Cyclobenzaprine Hydrochloride 1%, Dextromethorphan Hydrobromide 10%, Guaifenesin 10%, and Indomethacin 20% Penetrating Gel Vol. 12 No. 6 541
Glycerin, Sterile Vol. 12 No. 6 542
Indomethacin 2% in Pluronic Lecithin Organogel Vol. 12 No. 6 543
Ketorolac Tromethamine 2% Topical Gel Vol. 12 No. 6 544
Liothyronine Sodium (T3) 5-mcg/Hydrocortisone 5-mg Slow-Release Capsules Vol. 12 No. 6 545
Liothyronine Sodium (T3) 5-mcg/0.1-mL Transdermal Cream Vol. 12 No. 6 546
Liothyronine Sodium (T3) 5-mcg/Selenium 100-mcg Slow-Release Capsules Vol. 12 No. 6 547
Liothyronine Sodium (T3) 5-mcg Slow-Release Capsules Vol. 12 No. 6 548
Morphine Sulfate 20-mg and Prochlorperazine Maleate 10-mg Troches Vol. 12 No. 6 549
Physical Compatibility and Chemical Stability of a Concentrated Solution of Atropine Sulfate (2 mg/mL) for Use as an Antidote in Nerve Agent Casualties Vol. 12 No. 6 550
Chemical Stability of Admixtures Containing Ziconotide 25 mcg/mL and Morphine Sulfate 10 mg/mL or 20 mg/mL During Simulated Intrathecal Administration Vol. 12 No. 6 553
Stability of Metronidazole Benzoate in SyrSpend SF One-Step Suspension System Vol. 12 No. 6 558
PostScription: Supporting Compounding Around the World Vol. 12 No. 6 565